Hepatitis C virus (HCV) infection affects the liver and can lead to chronic complications, including cirrhosis and hepatocellular carcinoma. Therefore, early detection of HCV is crucial for preventing disease progression and viral transmission. However, conventional screening methods for HCV are time-consuming, requiring a two-step process involving detecting anti-HCV antibodies and quantifying HCV RNA.

A newly developed dual immunoassay addresses this limitation by enabling the simultaneous detection of anti-HCV antibodies and HCV antigens. Studies have demonstrated its efficiency in providing results comparable to the standard of care testing with high accuracy in a short diagnostic window. In this regard, Docplexus, Metropolis, and Roche have organized an informative session on “ Shaping the Future of Hepatitis C Diagnosis: The Role of the New HCV Ag-Ab Dual Assay ,” where reputed…